07:24:56 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-30 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 Ordinarie utdelning CSMED 0.00 DKK
2024-02-14 Bokslutskommuniké 2023
2023-12-15 Ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 Ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 Ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2023-09-06 08:30:00

CS MEDICA and RongShi strengthened the progress of their Joint Venture on its second Joint Fair at CPHI & PMEC in Guangzhou ,China 2023 (September 4-6), Asia's premier pharma event.

[image]

CS MEDICA, a leading MedTech company specializing in Cannabis and Pain Management, is excited to provide an update of its Joint Venture, RongShi MEDICA (Ordos) Co., Ltd. ("RongShi MEDICA", "JV" or "Joint Venture") - the Joint Venture partnership between CS MEDICA ("CS MEDICA" or "the Company") and Inner Mongolia Rong Shi Hi-Tech Co., Ltd ("RongShi").  

The Joint Venture has successfully participated in two prominent industry events:
  • In June,RongShi MEDICA made its fair debut at CPHI, China (19-21 June 2023) in Shanghai. This inaugural appearance at the world's nutraceutical event garnered the attention of approximately 15,000 industry experts from over 130 countries. The fair was a resounding success, resulting in valuable contacts and heightened awareness for the Joint Venture. Further CS MEDICA received inquiries from global and potential partners across the APAC region. Founders from both companies participated in the fair.
  • CPHI & PMEC, China (4-6 September 2023) in Guangzhou, South China Station. Like the fair in June, this fair offers extensive business opportunities in the Chinese pharmaceutical market.  During the fair severable, valuable leads were secured and engaged with potential customers. Additionally, numerous new opportunities emerged, and exciting discussions are underway.  Founders from both companies participated in the fair.

[image]

Lone Henriksen, CEO at CS MEDICA and Jason, Managing Director, RongShi MEDICA in joint conversation with an potential customer.

Lone Henriksen, CEO at CS MEDICA and Board member at RongShi MEDICA, states, "The continued success of our Joint Venture emphasizes the persistent commitment of CS MEDICA and RongShi to drive the future of healthcare in China and beyond. We eagerly anticipate furthering our accomplishments, cultivating fresh partnerships, and maintaining our position as pioneers in pharmaceutical innovation."

Jason, Managing Director, RongShi MEDICA, continues "We are thrilled to engage in productive interactions, meaningful discussions, and the establishment of strategic alliances at the current CPHI & PMEC China 2023 event. The engagement and will to win the Chinese market from CS MEDICA shows us that we collectively steer the course of healthcare's future in China and across the vast Asian market."

[image]